These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 16731915)

  • 21. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
    Yi CE; Ba L; Zhang L; Ho DD; Chen Z
    J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity.
    He Y; Li J; Jiang S
    Biochem Biophys Res Commun; 2006 May; 344(1):106-13. PubMed ID: 16615996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus.
    Hua RH; Wang YF; Bu ZG; Zhou YJ; Ge JY; Wang XJ; Tong GZ
    DNA Cell Biol; 2005 Aug; 24(8):503-9. PubMed ID: 16101348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.
    Zhou Z; Post P; Chubet R; Holtz K; McPherson C; Petric M; Cox M
    Vaccine; 2006 Apr; 24(17):3624-31. PubMed ID: 16497416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Potent neutralization antibody elicited in mice by SARS-associated coronavirus spike protein S1 domain].
    Zhang Y; Yang F; Li YH; Li WH; Tu XM; Wei Q; Zhu H; Liu L; Wang H; Qin C; Yuan GY; He W; Wang SH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):258-60. PubMed ID: 15640862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
    Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
    J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).
    Lai SC; Chong PC; Yeh CT; Liu LS; Jan JT; Chi HY; Liu HW; Chen A; Wang YC
    J Biomed Sci; 2005 Oct; 12(5):711-27. PubMed ID: 16132115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
    Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
    Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
    Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
    J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.
    Rockx B; Donaldson E; Frieman M; Sheahan T; Corti D; Lanzavecchia A; Baric RS
    J Infect Dis; 2010 Mar; 201(6):946-55. PubMed ID: 20144042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of two antigenic epitopes on SARS-CoV spike protein.
    Hua R; Zhou Y; Wang Y; Hua Y; Tong G
    Biochem Biophys Res Commun; 2004 Jul; 319(3):929-35. PubMed ID: 15184071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
    Keng CT; Zhang A; Shen S; Lip KM; Fielding BC; Tan TH; Chou CF; Loh CB; Wang S; Fu J; Yang X; Lim SG; Hong W; Tan YJ
    J Virol; 2005 Mar; 79(6):3289-96. PubMed ID: 15731223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.
    Du L; Zhao G; Li L; He Y; Zhou Y; Zheng BJ; Jiang S
    Biochem Biophys Res Commun; 2009 Jul; 384(4):486-90. PubMed ID: 19422787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.
    Goo J; Jeong Y; Park YS; Yang E; Jung DI; Rho S; Park U; Sung H; Park PG; Choi JA; Seo SH; Cho NH; Lee H; Lee JM; Kim JO; Song M
    Virus Res; 2020 Mar; 278():197863. PubMed ID: 31945421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS vaccine development.
    Jiang S; He Y; Liu S
    Emerg Infect Dis; 2005 Jul; 11(7):1016-20. PubMed ID: 16022774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening.
    Zhang X; Wang J; Wen K; Mou Z; Zou L; Che X; Ni B; Wu Y
    Viral Immunol; 2009 Dec; 22(6):407-15. PubMed ID: 19951177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
    Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
    J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.